Skip to main content
Clinical Trials/ACTRN12613001376730
ACTRN12613001376730
Not yet recruiting
Phase 3

A prospective, randomised comparison in hospitalised patients re-commenced on warfarin post-operatively at the usual maintenance dose versus a loading dose strategy to assess time to a stable therapeutic INR.

Flinders Medical Centre0 sites186 target enrollmentDecember 16, 2013

Overview

Phase
Phase 3
Intervention
Not specified
Conditions
Re-commencing post-operative warfarin
Sponsor
Flinders Medical Centre
Enrollment
186
Status
Not yet recruiting
Last Updated
6 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
December 16, 2013
End Date
TBD
Last Updated
6 years ago
Study Type
Interventional
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • \> 18 years old, receiving ongoing warfarin therapy, undergoing elective surgery, able to provide written, informed consent, and followed\-up by Hospital\-at\-Home services for INR monitoring

Exclusion Criteria

  • Unable to provide written, informed consent
  • Not followed\-up by Hospital\-at\-Home until a stable therapeutic INR is achieved
  • Undergoing cardiac surgery (note – patients with pre\-existing artificial mitral or aortic valves are eligible as long as the surgery is not cardiac)
  • Surgery expected to grossly prevent normal oral intake in the week post\-operatively eg colon resection
  • Use of more than 2 mg of vitamin K, fresh frozen plasma, or Prothrombinex\-VT for INR reversal immediately pre\-operatively
  • Use of any vitamin K, fresh frozen plasma, or Prothrombinex for INR reversal in the week after surgery, prior to a stable therapeutic INR being achieved. Normal blood transfusions are permissible and will be considered as a sub\-group.
  • Commencement of regular therapy with drugs known to interact with warfarin in the period between the most recently measured maintenance INR and the commencement of surgery, excluding routine drugs administered immediately prior to surgery, such as antibiotic prophylaxis. This includes, imidazole antifungals, macrolide antibiotics, fluoroquinolones, amiodarone, omeprazole, metronidazole, cholestyramine, carbamazepine, phenytoin, barbiturates, rifampicin, sulfamethoxizole/trimpethoprim, SSRI’s, thyroxine, NSAIDs.
  • Lack of reliable INR results with corresponding maintenance dose
  • Most recent routine maintenance dose INR below 1\.5 or above 3\.5 for patients with a therapeutic range of 2\-3, or above 4\.0 for patients with a therapeutic range of 2\.5\-3\.5
  • Warfarin reversed during warfarin re\-commencement period due to unexpected return to theatre

Outcomes

Primary Outcomes

Not specified

Similar Trials